Zymeworks Inc. (ZYME) stock
ZYMENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 5/30667% above fair value
$25.84−0.61 (-2.31%)
Close on Nov 17, 2026Market cap $1.83BP/E –Yield –
Zymeworks operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Zymeworks's operating income for the twelve months ending Jun 30, 2026 was -$155.56M. For fiscal 2025 it was -$92.55M. The highest annual figure on record is $130.53M in fiscal 2022.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$92.55M | – |
| FY2024 | Dec 31, 2024 | -$137.11M | – |
| FY2023 | Dec 31, 2023 | -$138.05M | -205.8% |
| FY2022 | Dec 31, 2022 | $130.53M | – |
| FY2021 | Dec 31, 2021 | -$215.63M | – |
| FY2020 | Dec 31, 2020 | -$187.47M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$42.18M | – |
| Q1 FY2026 | Mar 31, 2026 | -$47.12M | – |
| Q4 FY2025 | Dec 31, 2025 | -$44.15M | – |
| Q3 FY2025 | Sep 30, 2025 | -$22.11M | – |
| Q2 FY2025 | Jun 30, 2025 | -$674.00K | – |
| Q1 FY2025 | Mar 31, 2025 | -$25.61M | – |
| Q4 FY2024 | Dec 31, 2024 | -$22.22M | – |
| Q3 FY2024 | Sep 30, 2024 | -$34.21M | – |
| Q2 FY2024 | Jun 30, 2024 | -$42.89M | – |
| Q1 FY2024 | Mar 31, 2024 | -$37.80M | – |
| Q4 FY2023 | Dec 31, 2023 | -$23.42M | -107.3% |
| Q3 FY2023 | Sep 30, 2023 | -$33.24M | – |
| Q2 FY2023 | Jun 30, 2023 | -$54.11M | – |
| Q1 FY2023 | Mar 31, 2023 | -$27.28M | – |
| Q4 FY2022 | Dec 31, 2022 | $319.40M | – |
| Q3 FY2022 | Sep 30, 2022 | -$50.36M | – |
| Q2 FY2022 | Jun 30, 2022 | -$65.82M | – |
| Q1 FY2022 | Mar 31, 2022 | -$72.69M | – |
| Q4 FY2021 | Dec 31, 2021 | -$40.85M | – |
| Q3 FY2021 | Sep 30, 2021 | -$60.96M | – |
See a number that looks wrong?